Long-term complete remission in IgD-myeloma.
Long-term complete remission in IgD multiple myeloma (MM) is rare. This case report describes a patient with a stage IIIB IgD-MM, who was treated with conventional melphalan and prednisone chemotherapy. The monoclonal protein disappeared after four cycles and therapy was discontinued after 14 cycles. Re-evaluation after a follow up of more than 8 years demonstrates a continuing complete remission suggesting a cure. This is remarkable, considering that several adverse prognostic factors were present. In addition a concise review on IgD-MM is given.
Bemelmans
R H H
RH
Department of Internal Medicine, Gelre Hospitals, Apeldoorn, The Netherlands.
van Toorn
D W
DW
van Leeuwen
L
L
Schaar
C G
CG
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007072:Immunoglobulin D / Q000097:blood*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage*; D012074:Remission Induction / Q000379:methods
D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D007072:Immunoglobulin D; D008558:Melphalan; D011241:Prednisone